| 000 | 01851 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250512081115.0 | ||
| 264 | 0 | _c19860217 | |
| 008 | 198602s 0 0 eng d | ||
| 022 | _a0163-7258 | ||
| 024 | 7 |
_a10.1016/0163-7258(85)90013-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJeffrey, A M | |
| 245 | 0 | 0 |
_aDNA modification by chemical carcinogens. _h[electronic resource] |
| 260 |
_bPharmacology & therapeutics _c1985 |
||
| 300 |
_a237-72 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.; Review | ||
| 650 | 0 | 4 |
_a4-Nitroquinoline-1-oxide _xpharmacology |
| 650 | 0 | 4 |
_aAflatoxins _xpharmacology |
| 650 | 0 | 4 |
_aAlkylating Agents _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBenz(a)Anthracenes _xpharmacology |
| 650 | 0 | 4 |
_aBenzo(a)pyrene _xpharmacology |
| 650 | 0 | 4 |
_aBenzodiazepinones _xpharmacology |
| 650 | 0 | 4 |
_aBiotransformation _xdrug effects |
| 650 | 0 | 4 |
_aCarcinogens _xclassification |
| 650 | 0 | 4 | _aChemical Phenomena |
| 650 | 0 | 4 | _aChemistry |
| 650 | 0 | 4 |
_aChrysenes _xpharmacology |
| 650 | 0 | 4 |
_aDNA _ximmunology |
| 650 | 0 | 4 |
_aDNA Replication _xdrug effects |
| 650 | 0 | 4 |
_aEpoxy Compounds _xpharmacology |
| 650 | 0 | 4 |
_aFluorenes _xpharmacology |
| 650 | 0 | 4 |
_aFurocoumarins _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunologic Techniques |
| 650 | 0 | 4 |
_aIsotope Labeling _xmethods |
| 650 | 0 | 4 | _aMitomycin |
| 650 | 0 | 4 |
_aMitomycins _xpharmacology |
| 650 | 0 | 4 |
_aNaphthalenes _xpharmacology |
| 650 | 0 | 4 |
_aOxides _xpharmacology |
| 650 | 0 | 4 |
_aPlatinum _xpharmacology |
| 650 | 0 | 4 |
_aPyrenes _xpharmacology |
| 650 | 0 | 4 |
_aSafrole _xpharmacology |
| 650 | 0 | 4 | _aSpectrometry, Fluorescence |
| 773 | 0 |
_tPharmacology & therapeutics _gvol. 28 _gno. 2 _gp. 237-72 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0163-7258(85)90013-0 _zAvailable from publisher's website |
| 999 |
_c3941753 _d3941753 |
||